BP000988-PKA-234: Recombinant Human VEGFR1 D3
Source: Insect Cells-derived.
The activity of FLT1D1-3 was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces receptors, and in Far-Western and cross-linking experiments with iodinated VEGF.
Purity > 90%, by RP-HPLC and SDS-PAGE.BP000988-PKA-338: Recombinant Human VEGFR1 D3, His Tag
Source: Insect Cells-derived.
Purity > 95%, by RP-HPLC and SDS-PAGE.BP000989-PKA-235: Recombinant Human VEGFR1 D4
Source: Insect Cells-derived.
The activity of FLT1D1-4 was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces, and in Far-Western and cross-linking experiments with iodinated VEGF.
Purity > 90%, by RP-HPLC and SDS-PAGE.BP000990-PKA-239: Recombinant Human VEGFR1 D5
Source: Insect Cells-derived.
The activity of FLT1 D5 was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surfaces. The ED50 for this effect is typically 10 ng/ml, corresponding to a specific activity of 100,000IU/mg.
Purity > 90%, by RP-HPLC and SDS-PAGE.BP000991-PKA-241: Recombinant Human VEGFR1 D17
Source: Insect Cells-derived.
The activity of FLT1/Fc was determined by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells. The ED50 for this effect is typically 10-30 ng/ml, corresponding to a specific activity of 33,333.33-100,000 units/mg.
Purity > 95%, by SDS-PAGE.BP000992-PKA-240: Recombinant Human VEGFR1
Source: Insect Cells-derived.
The activity of FLT1 was determined by its ability to abolish the binding of iodinated VEGF to solid surfaces or cell surface receptors. The ED50 for this effect is typically 10 ng/ml, corresponding to a specific activity of 100,000IU/mg.
Purity > 90%, by RP-HPLC and SDS-PAGE.BP000992-PKA-354: Recombinant Human VEGFR1, His Tag
Source: E. coli-derived.
Purity > 95%, by SDS-PAGE.